Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome

Chest
David ShitritMordechai R Kramer

Abstract

Mycobacterium kansasii infection is one of the most common causes of nontuberculous mycobacterial lung disease in world. However, little is known about its background characteristics or drug sensitivity in nonendemic areas. We assessed the clinical features, radiologic findings, and drug sensitivity associated with M kansasii infection in Israel. Patients with a culture-positive diagnosis of M kansasii infection between April 1999 and April 2004 were identified from a clinic database of tuberculosis centers. Mycobacterial cultures were performed with standard methods. Data on patient background and clinical features were collected from the medical files. Mean age (+/- SD) of the 56 patients was 58 +/- 18 years, and 64% were men; 59% had associated lung disease. Fifteen percent were receiving immunosuppressive medications. None had HIV infection. Systemic comorbid diseases were noted in 27%. The most common clinical presentations were chest pain, cough, hemoptysis, fever, and night sweats. Cavitation was noted only in 54%. Older patients had more noncavitary disease than younger patients (p = 0.01, r = 0.35). Lower-lobe predominance was very rare (4%). None of the patients presented with pleural effusion or lymphadenopathy. Only...Continue Reading

References

Jul 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R W Shafer, M F Sierra
Dec 1, 1982·The Journal of Infectious Diseases·R C Good, D E Snider
Sep 1, 1981·Reviews of Infectious Diseases·E Wolinsky
Dec 20, 1999·Drugs·M R Jacobs
Oct 10, 2002·Clinics in Chest Medicine·David E Griffith

❮ Previous
Next ❯

Citations

Mar 8, 2012·Japanese Journal of Radiology·Masashi TakahashiKiyoshi Murata
Dec 14, 2011·Revue des maladies respiratoires·C AndréjakV Jounieaux
May 14, 2011·Respirology : Official Journal of the Asian Pacific Society of Respirology·Abdelkarim WanessAtul C Mehta
May 7, 2011·BMC Infectious Diseases·Gowri SatyanarayanaEric R Houpt
Apr 7, 2011·Internal Medicine·Masaaki AbeMikio Oka
Feb 7, 2008·Emerging Infectious Diseases·Manuel L Fernández-GuerreroMiguel Górgolas
Dec 22, 2006·Expert Review of Anti-infective Therapy·Jason E Stout
Dec 14, 2012·Expert Review of Respiratory Medicine·Curtis H Weiss, Jeffrey Glassroth
Jan 12, 2008·Chest·Jeffrey Glassroth
Apr 25, 2012·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jakko van IngenJohan W Mouton
Mar 12, 2016·Expert Review of Respiratory Medicine·Young Ae Kang, Won-Jung Koh
Apr 12, 2016·Tuberculosis and Respiratory Diseases·Yon Ju RyuCharles L Daley
Jul 16, 2015·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·T TsukataniK Matsumoto
Oct 20, 2012·Scandinavian Journal of Infectious Diseases·Bethany S DaviesHeather J Milburn
Oct 24, 2014·Future Microbiology·Jakko van Ingen, Ed J Kuijper
May 9, 2008·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Theresa A LagunaFrank J Accurso
Aug 2, 2012·Respiratory Medicine·Alona MatveychukDavid Shitrit
May 26, 2010·Yonsei Medical Journal·Hye Kyeong ParkO Jung Kwon
Oct 26, 2016·Radiologia brasileira·Roberto MogamiAgnaldo José Lopes
Nov 21, 2008·Postgraduate Medicine·Scott C ParrishAngeline Lazarus
Nov 26, 2009·Expert Opinion on Pharmacotherapy·Jaime Esteban, Alberto Ortiz-Pérez
Jul 7, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Charles L DaleyKevin L Winthrop
May 23, 2017·Current Treatment Options in Infectious Diseases·Julie V PhilleyEdward D Chan
Feb 14, 2018·Antimicrobial Agents and Chemotherapy·Zofia BakułaTomasz Jagielski
Feb 6, 2020·Frontiers in Microbiology·Tomasz JagielskiDominik Strapagiel
Aug 17, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Charles L DaleyKevin L Winthrop
Oct 16, 2013·Expert Review of Anti-infective Therapy·Jakko van IngenDick van Soolingen
Mar 5, 2019·Respiratory Medicine·Seong Mi MoonWon-Jung Koh
Nov 18, 2021·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Manasa VelagapudiMark A Malesker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.